Clinical trials: Major Depression Disorder
Major Depressive Disorder
Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer
The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.
- Trial name
- DETB (NCT02153281)
- Testing
- phenelzine treatment
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression
Patients with an episode of depression in late life prescribed mirtazapine recruited from a clinical sample will be monitored for weight and receive a blood test during their usual course of treatment to determine polymorphisms…
- Trial name
- NCT01601002
- Testing
- Mirtazapine
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Depressive Disorder, Major
Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
The proposed study is a randomized, placebo-controlled, double-blind trial to evaluate the safety and efficacy of antidepressant combination for the treatment of depression.
- Trial name
- COATS (NCT00150839)
- Testing
- Mirtazapine, Venlafaxine
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Major Depressive Disorders
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
Primary objective: To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD).
- Trial name
- NCT00855530
- Testing
- amibegron (SR58611A)
- Where
- 11 sites in Argentina, Chile and 9 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Unipolar Depression
Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression
The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test the relative safety of the combinations.
- Trial name
- NCT00179244
- Testing
- Rispridone (drug) and Bupropion ER (drug)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University
Major Depressive Disorder (MDD)
Context-Guided Personalized iTBS for Depression
The goal of this randomized clinical trial is to learn whether context-guided personalized intermittent theta burst stimulation (iTBS) works better than standard iTBS for adults with major depressive disorder.
- Trial name
- NCT07743398
- Testing
- Context-Guided Personalized Intermittent Theta Burst Stimulation, Standard Left DLPFC Intermittent Theta Burst Stimulation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Capital Medical University
Major Depressive Disorder (MDD)
6 Weeks Right-Amygdala TIS for Depression
The current investigation employs a directed neuromodulation technique, specifically targeting the right amygdala, to ascertain its therapeutic efficacy in managing depressive episodes.
- Trial name
- NCT07059143
- Testing
- Nervio-X
- Where
- 3 sites in China
- Volunteers
- 38 people
- Sponsor
- Ruijin Hospital
Depression
Treatments for Depression: Drug Versus Psychotherapy
This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
- Trial name
- NCT00043550
- Testing
- Supportive Expressive Therapy, Sertraline, Venlafaxine
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder
Mobile Apps for the Treatment of Depression
Smartphone applications (apps) may be well-suited as a low cost adjunctive tool for increasing the adherence of individuals to psychotherapy treatments which may subsequently increase symptom reduction and improve clinical…
- Trial name
- NCT02024620
- Testing
- Behavioral activation plus mobile app, Standard behavioral activation
- Where
- United States
- Sponsor
- Central Arkansas Veterans Healthcare System
Depression, Unipolar, Pain, Postoperative
Maternal Mindfulness: Depression and Postpartum Pain
This phase I clinical trial tests the feasibility and safety of a self-guided, mobile mindfulness-based intervention to reduce post-cesarean pain and prevent postpartum depression.
- Trial name
- MaMiDaPP (NCT05400382)
- Testing
- Mindfulness
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Urbana-Champaign
Major Depressive Disorder
A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for severe depression.
- Trial name
- NCT00422162
- Testing
- Duloxetine hydrochloride
- Where
- 35 sites in France, Italy and 2 more
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, MDD
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or…
- Conditions
- Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
- Trial name
- OBSERVER (NCT06512324)
- Testing
- Ampa One TMS System
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Biomedical Discoveries and Neuroscientific Foundations LLC
Major Depressive Disorder
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
- Trial name
- MAGELLAN (NCT01428661)
- Testing
- tasimelteon
- Where
- 40 sites in United States
- Volunteers
- 507 people
- Sponsor
- Vanda Pharmaceuticals
Sleep Disorders, Obstructive Sleep Apnea
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea…
- Conditions
- Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
- Trial name
- NCT00518986
- Testing
- armodafinil
- Where
- 62 sites in United States
- Volunteers
- 249 people
- Sponsor
- Cephalon
Depressive Disorder, Major
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01152996
- Testing
- Vortioxetine
- Volunteers
- 1,075 people
- Sponsor
- Takeda
Depressive Disorder, Major
A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
This study was designed to determine if the novel combination of the SSRI, sertraline, and the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable safety profile of SSRIs.
- Trial name
- NCT00636246
- Testing
- sertraline/[S,S]-reboxetine, sertraline, [S,S]-reboxetine monotherapy
- Where
- 17 sites in Estonia, Russia
- Volunteers
- 510 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder, Major
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.
- Trial name
- NCT04442490
- Testing
- SAGE-217
- Where
- 39 sites in United States
- Volunteers
- 543 people
- Sponsor
- Biogen
Depression, Postpartum
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
- Trial name
- NCT04442503
- Testing
- SAGE-217
- Where
- 82 sites in United States, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Biogen
PTSD, PTSD - Post Traumatic Stress Disorder
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PRE-EMPT will assemble a cohort of 150 participants from three populations (low risk, intermediate risk, and high risk for self-harm).
- Conditions
- PTSD, PTSD - Post Traumatic Stress Disorder, Major Depression, Suicidality
- Trial name
- PRE-EMPT (NCT07745569)
- Testing
- Transcranial Magnetic Stimulation, Psilocybin (drug), Neurofeedback
- Volunteers
- 150 people
- Sponsor
- University of New Mexico
Major Depressive Disorder
Repetitive Transcranial Magnetic Stimulation for Treating Depression: A Functional Magnetic Resonance Imaging Study
This protocol, "Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder (MDD): A Functional Connectivity Magnetic Resonance Imaging (fcMRI) Study," is an open-label pilot treatment…
- Trial name
- NCT01162382
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine